STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal

Pfizer is stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial.
Click here to view original post